Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Recruiting now · Phase 1

Conditions studied: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer

In brief

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS309 and the safety, dosimetry and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (BC), triple negative breast cancer (TNBC) and colorectal cancer (CRC).

Key facts

Study ID

NCT06562192

Run by

Novartis Pharmaceuticals

People needed

162

Starts

2024-10-15

Expected to finish

2031-01-16

Last updated by the study team

2026-07-29

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years old
• Patients with one of the following indications:
• Locally advanced unresectable or metastatic PDAC with disease progression following, or intolerance to cytotoxic chemotherapy, unless patient was ineligible to receive such therapy
• Locally advanced unresectable or metastatic NSCLC without any actionable genomic alterations with disease progression following, or intolerance to chemotherapy and immunotherapy, unless patient was ineligible to receive such therapy, or locally advanced unresectable or metastatic NSCLC with an actionable genomic alteration with disease progression following, or intolerance to targeted therapy, unless patient was ineligible to receive such therapy
• Locally advanced unresectable or metastatic HR+/HER2- ductal or lobular BC with disease progression following, or intolerance to, at least 2 lines of therapy, unless patient was ineligible to receive such therapy
• Locally advanced unresectable or metastatic TNBC with disease progression following, or intolerance to, at least 2 lines of therapy, unless patient was ineligible to receive such therapy
• Locally advanced or metastatic unresectable CRC with disease progression following, or intolerance to cytotoxic chemotherapy, unless patient was ineligible to receive such therapy. Patients with known microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status must also have had disease progression following, or intolerance to immune checkpoint inhibitor therapy, unless patient was ineligible to receive such therapy
• Patients must have lesions showing 68Ga-NNS309 uptake

You may not qualify if…

• Absolute neutrophil count (ANC) < 1.5 x 10\^9/L, hemoglobin < 9 g/dL, or platelet count < 100 x 10\^9/L
• QT interval corrected by Fridericia's formula (QTcF) ≥ 470 msec
• Calculated estimated glomerular filtration rate < 60 mL/min/1.73m2
• Unmanageable urinary tract obstruction or urinary incontinence
• Radiation therapy within 4 weeks prior to the first dose of [177Lu]Lu-NNS309
• Other protocol-defined inclusion/exclusion criteria may apply.

Where it is running

• Uni of Alabama at Birmingham — Birmingham, Alabama, United States (enrolling)
• University of California LA — Los Angeles, California, United States (enrolling)
• Stanford University Medical Center — Palo Alto, California, United States (enrolling)
• Mayo Clinic Jacksonville — Jacksonville, Florida, United States (enrolling)
• Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
• BAMF Health — Grand Rapids, Michigan, United States (enrolling)
• Mayo Clinic Rochester — Rochester, Minnesota, United States (enrolling)
• Uni Of TX MD Anderson Cancer Cntr — Houston, Texas, United States (enrolling)
• University Of Washington — Seattle, Washington, United States (enrolling)
• Novartis Investigative Site — Brussels, Belgium (enrolling)
• Novartis Investigative Site — Toronto, Ontario, Canada (enrolling)
• Novartis Investigative Site — Montreal, Quebec, Canada (enrolling)
• Novartis Investigative Site — Montreal, Quebec, Canada (enrolling)
• Novartis Investigative Site — Bron, France (enrolling)
• Novartis Investigative Site — Villejuif, France (enrolling)
• Novartis Investigative Site — Cologne, North Rhine-Westphalia, Germany (enrolling)
• Novartis Investigative Site — Essen, Germany (enrolling)
• Novartis Investigative Site — München, Germany (enrolling)
• Novartis Investigative Site — Rostock, Germany (enrolling)
• Novartis Investigative Site — Tel Aviv, Israel (enrolling)
• Novartis Investigative Site — Milan, MI, Italy (enrolling)
• Novartis Investigative Site — Reggio Emilia, RE, Italy (enrolling)
• Novartis Investigative Site — Nijmegen, Gelderland, Netherlands (enrolling)
• Novartis Investigative Site — Utrecht, Netherlands (enrolling)
• Novartis Investigative Site — Barcelona, Spain (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.